Almanac A1C

The Silent Global Crisis: How Metabolic Health Is Reshaping the Future of Female Breast Cancer

Posted

by

dr. Karunia Valeriani Japar

Table of Contents
Keywords: , , , , , ,

Introduction and Epidemiology

Breast cancer stands as the most commonly diagnosed cancer and a significant cause of cancer-related mortality among women worldwide, having surpassed lung cancer in incidence across many regions. As of 2025, it is estimated that approximately 3.2 million new breast cancer cases and 1.1 million related deaths will occur annually by 2050 if current trends persist, with much of the increase burdening countries with lower Human Development Index (HDI). Notably, breast cancer accounted for around 11.7% of all new cancer cases in women globally in 2020, illustrating its widespread health impact. Several factors-including genetic predisposition, hormonal influences, reproductive history, lifestyle behaviors, and environmental exposures- contribute to varying incidence patterns and outcomes between populations. The ongoing challenges in early detection, screening program coverage, and healthcare access are especially pronounced in low- and middle-income settings, where late-stage diagnosis and higher mortality rates persist [1,2,3,4,5,6].

Epidemiology and Incidence Patterns in Breast Cancer

Globally, the incidence of breast cancer continues to rise in both developed and developing countries, reflecting changes in population demographics, lifestyle factors, and the expanding reach of diagnostic screening. Recent analyses project that 1 in 20 women worldwide will be diagnosed with breast cancer in their lifetime. In high-income regions such as the United States and Western Europe, incidence rates have climbed, attributed partially to broad adoption of mammographic screening and increased longevity, while mortality rates have generally declined due to advances in treatment and earlier detection. Conversely, manly low- and middle-income nations are experiencing a disproportionate increase in both incidence and mortality, with limited access to screening and healthcare services contributing to late-stage presentation and poorer outcomes [3,4,5,7,8].

Figure 1. Breast Cancer in Asia in 2022 and Projections for 2050 [8]

Risk Factors and Prevention

Genetic and Non-Genetic Risk Factors

Breast cancer risk arises from an interplay of genetic predisposition and non-genetic influences. Genetic risk factors include pathogenic variants in high-penetrance genes such as BRCA1, BRCA2, PALB2, ATM, CHEK2, BARD1, RAD51C, RAD51D, and TP53, where carriers may face 2-8 fold increased lifetime risk. Furthermore, polygenic risk scores that aggregate common single-nucleotide variants can refine risk estimation, but performance varies across populations. Non-genetic risk determinants include age at menarche, parity, duration of breast feeding, family history, history of benign breast disease, height, BMI, alcohol consumption, reproductive hormone exposure, socioeconomic status, and ethnicity. For example, early menarche, late menopause, nulliparity, and postmenopausal obesity are established as elevating risk, while extended breastfeeding and physical activity are protective [9,10,11,12].

The Role of Metabolic Health in Breast Cancer Risk

Metabolic health plays a critical role in shaping breast cancer risk by modulating various energy and biosynthetic pathways. Tumor cells exhibit metabolic reprogramming- most notably increased glycolysis (Warburg effect), greater lactate production, altered pentose phosphate pathway activities for nucleotide synthesis, and enhanced glutaminolysis aiding amino acid supply and redox balance. Obesity-associated metabolic alterations include chronic inflammation, insulin resistance, hyperinsulinemia, and excess estrogen production, facilitating tumorigenesis. Metabolomic studies reveal that aggressive breast cancers (especially TNBC and HER2+) display distinctive profiles of energy metabolism, heightened glycolysis and glutaminolysis, and enhanced fatty acid synthesis compared to less aggressive subtypes. Notably, these metabolic shifts also produce metabolites that affect proliferation, migration, and therapy response [13,14,15,16,17].

Figure 2. Molecular Changes Affecting Breast Cancer Progression in Women With Metabolic Syndrome [14]

Modifiable Lifestyle Determinants: Diet, Exercise and Obesity

Nearly a third of breast cancer cases can be attributed to modifiable lifestyle factors including diet, physical activity, and obesity. Diets rich in vegetables, whole grains, and lean protein appear to confer protection, while high intake of red and processed meats, saturated fats, and excess alcohol increase risk. Regular exercise reduces risk by improving insulin sensitivity, reducing body fat, and dampening chronic inflammation. Obesity, particularly in postmenopausal women, elevates breast cancer risk by increasing peripheral aromatization of androgens to estrogens and promoting growth factors that stimulate cancer cell proliferation. Intervention that combine weight management and physical activity display synergistic reductions in breast cancer incidence and recurrence risk [10,18,19,20,21].

Endocrine and Metabolic Disorders Associated with Breast Cancer

Several endocrine and metabolic disorders are implicated in breast cancer development and outcomes. *Type 2 diabetes, metabolic syndrome,*and  insulin resistance have each been independently associated with increased incidence, facilitated by chronic hyperinsulinemia, increased IGF-1 signaling, and systemic inflammation/ disorders of ovarian function such as PCOS, thyroid dysfunction and other hormonal imbalances (including excess estrogen) may further elevate risk due to altered hormone environments that stimulate breast epithelium. Women with non-obese metabolic dysfunction ( high triglycerides, glucose, hypertension) may face higher risks than non-obese controls, highlighting the complexity of metabolic health beyond adiposity alone. Preventive strategies must target metabolic disorders through improved glycemic control healthy diet, regular exercise, and appropriate screening for endocrine abnormalities [13,14,22,23,24].

Pathophysiology and Molecular Mechanisms

Molecular Subtypes and Pathogenesis of Breast Cancer

Breast cancer is a heterogenous disease with several distinct molecular subtypes: luminal A, luminal B, HER2-positive, basal-like, and triple -negative breast cancer (TNBC). Each subtype is defined by unique gene expression profiles, immune status, and drivers, with therapeutic and prognostic implications. Luminal subtypes are characterize by estrogen and progesterone receptor positivity and relatively slower progression, whereas HER2-positive tumors overexpress the HER2 oncogene, often leading to aggressive disease but with targeted therapy options. TNBC LACKS expression of ER, PR and HER2, and is molecularly diverse (basal0like, mesenchymal, immunomodulatory), marked by high genetic and epigenetic instability, altered DNA repair, and clonal evolution fueled by both intrinsic and external factors [25,26,27,28,29].

Metabolic Reprogramming in Breast Cancer Cells

A hallmark of breast cancer cells is metabolic reprogramming, which promotes rapid proliferation and survival under adverse conditions. Key features include enhanced glycolysis (“Warburg effect”), increased glutaminolysis, and upregulated lipid and amino acid metabolism. These changes allow cancer cells to generate biosynthetic precursors, maintain redox homeostasis, and resist apoptosis. The upregulation of glucose uptake and lactate export (via GLUT1, LDHA) supplies energy and building blocks, while lipid metabolism shifts (fatty acid synthase, SREBP1 upregulation) support membrane synthesis and signaling. Amino acid metabolic rewiring-especially of glutamine, serine, glycine, and arginine-supports rapid growth and therapy resistance. Metabolic targeting is increasingly viewed as a clinical strategy against breast cancer [15,30,31,32].

Hormonal Regulation and the Tumor Microenvironment

Hormonal regulation primarily through estrogen and progesterone-directly influences breast epithelial cell proliferation, differentiation, and survival. The tumor microenvironment (TME) comprises stromal cells, immune infiltrates, extracellular matrix, all of which actively interact with cancer cells and mediate therapy response. In hormone receptor-positive cancers, endocrine factors coordinate stromal remodeling, angiogenesis, and immune exclusion-fostering tumor growth and treatment resistance. Conversely, hormone-insensitive tumors (e.g., TNBC) present distinct, more immunogenic microenvironments with greater stromal diversity and immune infiltration. Paracrine signaling between cancer and TME components (fibroblast, adipocytes, immune cells) modifies extracellular matrix composition, promotes invasion, and shapes resistance mechanisms [33,34,35,36].

Inflammation, Insulin Resistance, and Carcinogenesis

Chronic inflammation and insulin resistance are critical contributors to breast cancer initiation and progression. Obesity, metabolic syndrome, and type 2 diabetes create a pro-inflammatory environment marked by elevated TNF-a, IL-6, CRP, and leptin, which activate signaling pathways (e.g., NF-kB, JAK/STAT) driving transformation and proliferation. Insulin resistance results in hyperinsulinemia and increased IGF-1, both of which have mitogenic and anti-apoptotic effects on breast epithelial cells, fostering genomic instability and carcinogenesis. Adipokine imbalances (e.g., reduced adiponectin, increased leptin) further facilitate local and systemic inflammation, angiogenesis, and tumor cell survival [37,38,39].

Screening, Early Detection, and Diagnosis

Advances in Screening Techniques and Early Detection

Recent updates in breast cancer screening guidelines emphasize personalized, risk-based approaches beginning at age 40, rather than a one size fits all model. Screening intervals now consider individual risk profiles- including genetics, breast density, and family history to optimize detection and minimize unnecessary interventions. Mammography remains the gold standard, particularly with the widespread adoption of digital breast tomosynthesis (3D mammography), which improves sensitivity for dense breast tissue and reduces recall rates. Supplemental imaging modalities, such as ultrasound and MRI, are increasingly integrated for high risk populations and those with dense breast, enhancing sensitivity and specificity. Emerging wearable technologies and sensor-based diagnostics- such as smart bras and real time biosensors offer potential for more accessible, frequent, and non invasive screenings, particularly in resource limited or rural settings [40,41,42,43].

Breast self examination (BSE) plays a critical role in early breast cancer detection within low and middle income countries, where limitations in access to mammography and clinical breast examination hinder comprehensive screening. BSE is a simple, low cost, and non invasive method enabling women to identify abnormalities and lumps before clinical symptoms develop, with regular monthly practice recommended starting at age 20. In regions where advanced screening modalities remain scarce, more than 90% of breast cancer cases can potentially be detected by women themselves if adequate awareness and education strategies are employed. However, actual BSE practice rates remain low, often below 20% due to socioeconomic barriers, limited health literacy, and cultural factors that dampen participation, particularly among rural and lower income groups. Improving education, leveraging community outreach, and integrating digital and social media campaigns have proven effective, but ongoing investment is needed for wider adoption and to bridge awareness gaps in underserved populations [44,45,46,47,48].

This context underlines the urgent necessity to pair technological advances in screening and digital diagnostics with robust initiatives supporting self-examination, particularly in resource-constrained populations, to foster earlier presentation and improved survival outcomes. Breast self examination (BSE) remains an essential screening method in low and middle income countries, where access to mammography and clinical is often limited by cost, healthcare infrastructure and trained personnel. BSE is a low-cost, non-invasive approach that empowers women to identify lumps or changes in their breast at early stages, potentially detecting over 90% of cases through self-awareness and regular monthly practice. Despite its promise, rates of BSE practice remain o, frequently below 20% due to barriers like insufficient education, low health literacy, cultural stigma, and poor socioeconomic status, which are particularly pronounced in rural and underserved areas. Successful programs in these regions emphasize community based education, targeted outreach by healthcare professionals, use of local media and integration with social media platforms to boost awareness and practice [45,47,49].

Integrating breast self-examination with advances in digital, mobile outreach and ongoing education initiatives is vital to improving early detection rates and survival outcomes in third world countries, complementing technological progress in screening [45,47].

AI and Digital Health Innovations in Breast Cancer Diagnosis

Artificial intelligence and digital health are rapidly transforming breast cancer diagnosis, improving accuracy, speed, and patient outcomes across the screening and pathology workflow. AI-powered algorithms now match or exceed expert radiologists in mammogram analysis, with deep learning models shown to reduce false positives and false negatives while identifying subtle lesion missed by humans, these tools support radiologist by highlighting suspicious regions, standardizing interpretations across institutions, and facilitating double reading. In pathology, digital image analysis powered by AI enables automated grading, classification of molecular subtypes, quantitation of biomarkers, and rapid detection of lymph nodes metastases, streamlining diagnostic decision and prognostic assessment. AI is also advancing liquid biopsy interpretation, risk stratification, and integration of molecular data for personalized medicine. Integration of AI with wearable monitoring and telehealth platforms further enhances early detection, patient engagement, and care delivery beyond hospital settings [48,49,50,51,52,53].

Lifestyle Medicine as an Adjunct to Conventional Treatment

Lifestyle medicine, encompassing evidence-based practices in nutrition, physical activity, stress management, sleep hygiene, social connection, and avoidance of risky substances, is increasingly recognized as a valuable adjunct to conventional breast cancer therapy, enhancing both clinical outcomes and quality of lifestyle interventions have demonstrated improvement in metabolic health, symptom management, and psychological well-being when integrated alongside standard treatments such as chemotherapy, radiotherapy, hormone therapy, and surgery [54,55,56,57,58].

Dietary strategies, particularly those based on the Mediterranean diet, have shown benefit in reducing body mass index (BMI), improving lipid profiles, and alleviating menopausal symptoms among breast cancer survivors. Increased intake of fiber, omega03 fatty acid, and fermented foods is associated with enhanced energy and reduced fatigue, while better adherence to plant-predominant diets may lower recurrence risk and support metabolic health post-treatment. Regular, tailored exercise regimens not only ameliorate treatment-related fatigue but also optimize strength, independence, and overall health, with structured programs improving physical functioning and long-term well-being [54,55,56,59,60].

Psychosocial support including stress reduction techniques, mindfulness, and professional counseling mitigates anxiety, depression, and the psychological burden of cancer diagnosis and therapy, fostering resilience and better adherence to medical protocols. Restorative sleep and strong social connection further influence recovery, with multidisciplinary clinics demonstrating positive synergistic effects when addressing all pillars of lifestyle medicine. Recent research highlights that integrating these intervention after conventional treatment results in high patient satisfaction, improved confidence in self-management, and measurable enhancement in metabolic markers [54,56,57,58].

The development of oncology-focused lifestyle medicine programs exemplifies a paradigm shift toward holistic survivorship care, with mounting evidence for their utility in sustaining remission, managing side effects, and lowering the risk of comorbidities such as cardiovascular disease and bone loss. Ongoing research and multidisciplinary collaboration are critical for further optimizing these integrated approaches and overcoming barriers to widespread implementation within clinical oncology [54,55,56,57,60].

Survivorship, Long-term Outcomes, and Prevention of Recurrence

Quality of Life, Rehabilitation, and Supportive Care

Long term breast cancer survivors face a spectrum of physical, psychological, and social challenges that persist well beyond active treatment. Most survivors report ongoing symptoms, such as fatigue, chronic pain, lymphedema, sleep disturbances, and cognitive impairment, all of which may negatively impact overall quality of life (QoL). Psychosocial issues including anxiety, depression, fear of recurrence, and difficulties with social or occupational reintegration are also common and require ongoing support. Unfortunately, many current clinical practice guidelines overlook the full complexity of these survivorship needs, underscoring the critical importance of patient centered, multidisciplinary care approaches [61,62].

Rehabilitation is essential for maximizing functional recovery and mitigating long term adverse effects in breast cancer survivors. Individualized rehabilitation interventions encompassing physiotherapy, exercise, patient education, psychosocial counseling, and vocational support have consistently been shown to improve physical performance, emotional well-being, social functioning, and QoL. Evidence supports that integrating structured rehabilitation services early and throughout survivorship is associated with better treatment adherence, increased self-efficacy, and enhanced psychosocial resilience. Nurses and allied health providers are central to coordinating these interventions and bridging gaps in care [63,64,65].

Secondary Prevention and Metabolic Health Optimization

Secondary prevention strategies such as surveillance for recurrence, managing late treatment effects, and optimizing metabolic health are vital for improving long-term outcomes. Recent evidence strongly links the presence of metabolic syndrome components (obesity, insulin resistance, dyslipidemia, hypertension, and diabetes) with higher recurrence rates and worse survival among breast cancer survivors. Adoption of a low fat or Mediterranean style diet, regular moderate to vigorous exercise, and weight management are associated with reduced recurrence, improved treatment response, and decreased all-cause mortality, particularly in those with coexisting metabolic risk factors. Ongoing risk assessments, healthy lifestyle counseling, and metabolic monitoring should be routine parts of survivorship care [62,66,67].

The Role of Digital Health in Survivorship Monitoring

Digital health technologies, ranging from telehealth visits and remote patient monitoring platforms to apps and wearables are revolutionizing the way survivorship care is delivered. Recent trials have demonstrated that integrated remote monitoring of symptoms, physiological parameters, and patient reported outcomes can lead to improved QoL, earlier identification and management of adverse effects, fewer unplanned hospital visits, and greater patient engagement. Smartwatches and home-based connected devices allow tracking of heart rate, activity, sleep, and medication adherence, while eHealth programs deliver education, psychosocial support, and lifestyle coaching on demand. Despite technical and access barriers, the rapid expansion of digital survivorship platforms has the potential to optimize monitoring, personalize risk management, and support self-care practices globally [68,69,70].

Future Directions and Public Health Perspectives

Innovations in Breast Cancer Prevention Research

Cutting edge research is driving a new era in breast cancer prevention by harnessing advances in molecular biology, immunology and digital health. Notable innovations include the development of breast cancer vaccines targeting tumor associated antigens such as HER2, MUC1, and hTERT, using platforms like mRNA and engineered peptides-these aim to stimulate immune responses and reduce recurrence in high risk and post treatment settings. Additionally, precision medicine using omics-based biomarkers, AI powered risk stratification, microbiome manipulation and nanotherapeutics is enabling more individualized risk prediction and intervention strategies, especially for aggressive and difficult to treat subtypes. Equitable access to innovative research, streamlined international clinical trials, and policy reforms remain vital to ensure that breakthroughs benefit diverse global populations [71,72,73,74,75,76,77].

Population-wide Screening Programs and Policy Implications

Population wide screening particularly mammography remains the cornerstone of early detection and mortality reduction in breast cancer, with significant population level benefit when coverage and participation are high. Policy frameworks in many countries now support risk-adapted screening for women ages 40-74, incorporating genetic testing and subsidized preventive medications for high-risk individuals. However, persistent challenges include disparities in screening uptake due to socioeconomic barriers, cultural factors, insurance coverage, and access in remote or resource-limited regions. Meta-analysis of interventions shows that educational campaigns, reminders, navigations services, and culturally sensitive approaches can markedly increase mammography participation and reduce inequities, especially among underserved and minority populations [78,79,80].

Raising Awareness and Health Promotion Strategies

Public health strategies focused on raising awareness underpin effective prevention and early detection efforts worldwide. Annua campaigns such as Breast Cancer Awareness Month (BCAM) use mass media, educational events, and community outreach to educate about risk factors, promote regular screening, and encourage healthy behavior changes. Studies highlight the effectiveness of combining printed materials, seminars, interactive forums, and digital platforms to enhance knowledge, attitudes, and early adoption of screening behaviors, including breast self examination and clinical breast examination. Global initiatives from WHO and cancer organizations emphasize health promotion, timely diagnosis, and comprehensive management as pillars to improve survival and quality of life for all individuals at risk. Policy and practice must continue to address the need for targeted messaging, sustainable funding, and robust metrics for evaluating campaign impact [81,82,83].

Conclusion

Breast cancer has epidemiological significance, pathophysiological complexity, and multifaceted risk factors, with an emphasis on the increasing burden in low and middle income countries. The synthesis underscores how both genetic and modifiable lifestyle factors such as diet, exercise, obesity, and metabolic health play crucial roles in disease onset and outcomes. Breast cancer is marked by molecular heterogeneity, metabolic reprogramming, and complex interactions within the tumor microenvironment, which collectively influence progression, therapeutic resistance, and long term survival.

Advances in screening, such as risk based mammography, digital imaging, and wearable technologies, along with vital role of breast self-examination particularly in resource limited settings are pivotal for early detection. The integration of artificial intelligence and digital health solutions are reshaping diagnostic pathways, increasing accuracy and access to personalized care. Lifestyle medicine, incorporating evidence based nutrition, physical activity, and psychosocial support , is recognized as valuable adjunct to conventional treatment, improving quality of life, metabolic health, and survivorship.

Long term outcomes and survivorship are shaped by ongoing rehabilitation, supportive care, and robust secondary prevention strategies targeting metabolic syndrome and recurrence risk. Digital health innovations, including remote monitoring and telehealth, are transforming survivorship care and self-management. The document concludes by outlining future directions-such as vaccine development, precision prevention, and equitable to access to innovations as well as public health imperatives, including population wide screening, policy enhancement, and multipronged awareness campaigns. Together, these strategies are essential for reducing the global burden of breast cancer, improving survival, and enhancing the lives of those affected.

References

  1. Xu H, Xu B. Breast cancer: Epidemiology, risk factors and screening. Chinese Journal of Cancer Research. 2023 Jan 1;35(6):565–83.
  2. Xu Y, Gong M, Wang Y, Yang Y, Liu S, Zeng Q. Global trends and forecasts of breast cancer incidence and deaths. Scientific Data [Internet]. 2023 May 27;10(1):334. Available from: https://www.nature.com/articles/s41597-023-02253-5
  3. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians [Internet]. 2025 Jan 16;75(1). Available from: https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21871
  4. Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nature Medicine [Internet]. 2025 Feb 24;31(4). Available from: https://www.iarc.who.int/wp-content/uploads/2025/02/pr361_E.pdf?utm_source=chatgpt.com
  5. Huang J, Chan PS, Lok V, Chen X, Ding H, Jin Y, et al. Global incidence and mortality of breast cancer: a trend analysis. Aging. 2021 Feb 11;13(4).
  6. Xu S, Liu Y, Zhang T, Zheng J, Lin W, Cai J, et al. The Global, Regional, and National Burden and Trends of Breast Cancer From 1990 to 2019: Results From the Global Burden of Disease Study 2019. Frontiers in Oncology. 2021 May 21;11.
  7. Breast cancer cases and deaths are projected to rise globally [Internet]. Who.int. 2025. Available from: https://www.iarc.who.int/news-events/breast-cancer-cases-and-deaths-are-projected-to-rise-globally/
  8. Fu M, Peng Z, Wu M, Lv D, Li Y, Lyu S. Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050. The Breast. 2025 Feb;79:103835.
  9. Yeo W, Yuen LW, Tsoi KKF, Chan EYY, Kwok CC, Soong I, et al. Modifiable Risk Factors Including Self-Perceived Stress for Breast Cancer in Hong Kong: A Case-Control Study of 10 757 Subject. Clinical Medicine Insights Oncology. 2025 Jan 1;19.
  10. Lammert J, Grill S, Kiechle M. Modifiable Lifestyle Factors: Opportunities for (Hereditary) Breast Cancer Prevention – a Narrative Review. Breast Care [Internet]. 2018;13(2):109–14. Available from: https://www.karger.com/Article/FullText/488995
  11. Guo W, Li JL, McClellan J, Atara Ntekim, Oladosu Ojengbede, Temidayo Ogundiran, et al. Genetic and Nongenetic Risk Factors for Breast Cancer Risk Estimation. JAMA Network Open [Internet]. 2025 Apr 18 [cited 2025 Jun 6];8(4):e255804–4. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832972?utm
  12. Guo W, Li JL, McClellan J, Atara Ntekim, Oladosu Ojengbede, Temidayo Ogundiran, et al. Genetic and Nongenetic Risk Factors for Breast Cancer Risk Estimation. JAMA Network Open [Internet]. 2025 Apr 18;8(4):e255804–4. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832972?utm
  13. da Silva-Filho PPP, Buttros DAB, Buttros LAB, Esperança G, Gubolino PLF, Carvalho-Pessoa E, et al. High Risk of Metabolic Dysfunction in Nonobese Breast Cancer Survivors. Clinical Breast Cancer [Internet]. 2025 Jan 27;25(4):e479–86. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1526820925000199
  14. Harborg S, Larsen HB, Elsgaard S, Borgquist S. Metabolic syndrome is associated with breast cancer mortality: A systematic review and meta‐analysis. Journal of Internal Medicine. 2025 Jan 8;297(3):262–75.
  15. Garg P, Singhal G, Horne D, Salgia R, Singhal SS. Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer [Internet]. 2025 Jul 21;1880(5):189396. Available from: https://www.sciencedirect.com/science/article/pii/S0304419X25001386
  16. Wang L, Zhang S, Wang X. The Metabolic Mechanisms of Breast Cancer Metastasis. Frontiers in Oncology. 2021 Jan 7;10.
  17. Subramani R, Poudel S, Smith KD, Estrada A, Lakshmanaswamy R. Metabolomics of Breast Cancer: A Review. Metabolites. 2022 Jul 13;12(7):643.
  18. Brown J. Diet and Breast Cancer Risk | Breast Cancer Research Foundation [Internet]. Breast Cancer Research Foundation. 2025. Available from: https://www.bcrf.org/about-breast-cancer/breast-cancer-diet-nutrition/
  19. Cancer Australia. Lifestyle factors [Internet]. Cancer Australia. 2018. Available from: https://www.canceraustralia.gov.au/breast-cancer-risk-factors/modifiable-factors/lifestyle-factors
  20. Marino P, Mininni M, Deiana G, Marino G, Divella R, Bochicchio I, et al. Healthy Lifestyle and Cancer Risk: Modifiable Risk Factors to Prevent Cancer. Nutrients. 2024 Jan 1;16(6):800.
  21. Yeo W, Yuen LW, Tsoi KKF, Chan EYY, Kwok CC, Soong I, et al. Modifiable Risk Factors Including Self-Perceived Stress for Breast Cancer in Hong Kong: A Case-Control Study of 10 757 Subject. Clinical Medicine Insights Oncology. 2025 Jan 1;19.
  22. Zooravar D, Radkhah H, Amiri BS, Soltani P. Association Between Triglyceride‐Glucose Index and Breast Cancer: A Systematic Review and Meta‐Analysis. Cancer Reports. 2025 Apr;8(4).
  23. parveen DN, Bibi DR, Amina, Najam DA, Mahboob DS, Shams DA. IMPACT OF METABOLIC AND ENDOCRINE DISORDERS ON UTERINE AND OVARIAN CANCER RISK: A SYSTEMATIC REVIEW AND META-ANALYSIS. Journal of Population Therapeutics and Clinical Pharmacology [Internet]. 2023 [cited 2025 Sep 25];32(6):163–7. Available from: https://www.jptcp.com/index.php/jptcp/article/view/10667
  24. Hawazie A, Druce M. Breast Cancer Risk and Management in the Endocrine Clinic: A Comprehensive Review. Clinical Endocrinology. 2025 Feb 4;
  25. Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduction and Targeted Therapy [Internet]. 2025 Feb 19;10(1). Available from: https://www.nature.com/articles/s41392-024-02108-4
  26. Orrantia-Borunda E, Anchondo-Nuñez P, Acuña-Aguilar LE, Gómez-Valles FO, Ramírez-Valdespino CA. Subtypes of Breast Cancer [Internet]. Mayrovitz HN, editor. PubMed. Brisbane (AU): Exon Publications; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK583808/
  27. Tapia-Uriol P, Becerra-Goicochea L, Campos-Valderrama V, del Valle-Mendoza J, Aguilar-Luis MA, Silva-Caso WG. Characterization of intrinsic subtypes of breast cancer and their relationship with staging: an observational study. Frontiers in Medicine. 2025 May 9;12.
  28. Kim ES. Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review). International Journal of Oncology [Internet]. 2025 May 27;66(6):1–20. Available from: https://www.spandidos-
  29. Dogra AK, Prakash A, Gupta S, Gupta M. Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review. Meme sağlığı dergisi/Meme sağlığı dergisi [Internet]. 2025 Mar 3; Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11934825/
  30. Audrito V, Giovannetti E. Editorial: Metabolic reprogramming in cancer. Frontiers in Pharmacology. 2025 Mar 11;16.
  31. Wang M, Zhang Y, Li Z, Fu L. Reprogramming of amino acid metabolism in breast cancer. Biochimica et biophysica acta Reviews on cancer [Internet]. 2025 Oct;1880(5):189412. Available from: https://pubmed.ncbi.nlm.nih.gov/40780461/
  32. Wu X, Tan X, Bao Y, Yan W, Zhang Y. Landscape of metabolic alterations and treatment strategies in breast cancer. Genes & Diseases [Internet]. 2025 Jan 8;101521. Available from: https://www.sciencedirect.com/science/article/pii/S2352304225000108
  33. Ferreira Almeida C, Correia-da-Silva G, Teixeira N, Amaral C. Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies. Biochemical Pharmacology [Internet]. 2024 Mar 30;223:116178. Available from: https://www.sciencedirect.com/science/article/pii/S0006295224001618
  34. Yuan J, Yang L, Li Z, Zhang H, Wang Q, Huang J, et al. The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer. Frontiers in Endocrinology [Internet]. 2023 [cited 2023 Nov 14];14:1261283. Available from: https://pubmed.ncbi.nlm.nih.gov/37900137/
  35. Diaz I, María José Gattas, Laporte T, Tanaka M, Simian M. The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer. Frontiers in Endocrinology. 2019 Aug 8;10.
  36. Sarah Theresa Boyle. RISING STARS: Hormonal regulation of the breast cancer microenvironment. Journal of molecular endocrinology. 2023 Apr 1;70(3).
  37. Jeyakumar E, Sundararaju S, Annett S, Elrayess MA. Mammary Adipose Dysfunction in the Dual Epidemic of Obesity and Breast Cancer. Carcinogenesis [Internet]. 2025 Mar;bgaf053. Available from: https://pubmed.ncbi.nlm.nih.gov/40899258/
  38. Ruan GT, Xie HL, Hu CL, Liu CA, Zhang HY, Zhang Q, et al. Comprehensive prognostic effects of systemic inflammation and Insulin resistance in women with breast cancer with different BMI: a prospective multicenter cohort. Scientific reports. 2023 Mar 15;13(1).
  39. Bloomgarden Z. Insulin Resistance and Cancer. Journal of Diabetes [Internet]. 2025 Feb 1 [cited 2025 Jun 6];17(2). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11862885/?utm_source=chatgpt.com
  40. Aboagye SO, Hunt JA, Ball G, Wei Y. Portable noninvasive technologies for early breast cancer detection: A systematic review. Computers in Biology and Medicine. 2024 Nov;182:109219.
  41. Khan AQ, Touseeq M, Rehman S, Tahir M, Ashfaq M, Jaffar E, et al. Advances in breast cancer diagnosis: a comprehensive review of imaging, biosensors, and emerging wearable technologies. Frontiers in Oncology. 2025 Jun 18;15.
  42. Routine Breast Cancer Screening Brings Better Outcomes for Patients [Internet]. Rsna.org. 2025. Available from: https://www.rsna.org/news/2025/may/breast-screening-brings-better-outcomes
  43. Gul S. Breast Cancer Screening Guidelines: What’s Changed in 2025? [Internet]. Massive Bio. 2025 [cited 2025 Sep 26]. Available from: https://massivebio.com/breast-cancer-screening-guidelines-whats-changed-in-2025/
  44. Ayaad O, Ajmi A, Khalid Al Baimani, Eyad Abu Alhaijaa, Ibrahim R, Salim Nasser AlDhahli, et al. Breast Cancer Awareness, Screening Practices, Barriers, and Educational Interventions in Middle Eastern Countries: Challenges and Successes. Asian Pacific Journal of Cancer Biology [Internet]. 2025;10(2):251–60. Available from: http://waocp.com/journal/index.php/apjcb/article/view/1672
  45. Ishtiak ASM, Ahmed N, Gaffar F, Khan MdAS, Yasmeen F. Knowledge, practice and associated factors of breast self-examination among female university students of Bangladesh. Heliyon. 2022 Nov;8(11):e11780.
  46. Pippin MM, Boyd R. Breast Self Examination [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK565846/
  47. Baykemagn ND, Alemayehu MA, Yehuala TZ, Walle AD, Gedefaw AE, Mengistu AK. Predicting breast self-examination awareness in Sub-Saharan Africa using machine learning. Scientific Reports [Internet]. 2025 Jun 4;15(1). Available from: https://www.nature.com/articles/s41598-025-03112-6
  48. Thaineua V, Ansusinha T, Auamkul N, Taneepanichskul S, Urairoekkun C, Jongvanich J, et al. Impact of regular Breast Self‐Examination on breast cancer size, stage, and mortality in Thailand. The Breast Journal [Internet]. 2019 Sep 6;26(4). Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/tbj.13611
  49. Aliyi M, Hotessa Y, Haro A, Beyene BN, Desalegn M, Debela DE. Breast self-examination practice and associated factors among pastoralist women in the West Guji Zone, Oromia, Ethiopia: a community-based cross-sectional study. Frontiers in Global Women’s Health. 2025 Mar 20;6.
  50. Dur Karasayar AH, Kulaç İ, Kapucuoğlu N. Advances in Breast Cancer Care: The Role of Artificial Intelligence and Digital Pathology in Precision Medicine. European Journal of Breast Health [Internet]. 2025 Mar 3 [cited 2025 Mar 28]; Available from: https://www.eurjbreasthealth.com/articles/advances-in-breast-cancer-care-the-role-of-artificial-intelligence-and-digital-pathology-in-precision-medicine/doi/ejbh.galenos.2025.2024-12-8
  51. Suzanne, Peters J, Janssen N, Kroes J, Loehrer EA, Gommers J, et al. AI as an independent second reader in detection of clinically relevant breast cancers within a population-based screening programme in the Netherlands: a retrospective cohort study. The Lancet Digital Health [Internet]. 2025 Aug 1 [cited 2025 Sep 16];100882–2. Available from: https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00064-0/fulltext?utm_
  52. Rigby E, Vidya R, Shaaban AM. Use of digital pathology and artificial intelligence (AI) in breast cancer diagnosis and management: opportunities and challenges. Diagnostic Histopathology. 2025 Jan;
  53. Khan AQ, Touseeq M, Rehman S, Tahir M, Ashfaq M, Jaffar E, et al. Advances in breast cancer diagnosis: a comprehensive review of imaging, biosensors, and emerging wearable technologies. Frontiers in Oncology. 2025 Jun 18;15.
  54. Wright LE, Sudheendra PK. Evidence for the benefits of lifestyle medicine interventions in breast cancer survivorship. The Oncologist [Internet]. 2024 Dec 3 [cited 2024 Dec 14]; Available from: https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyae303/7915797
  55. Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Philip EJ, Ferrari R, Peixoto RM, Crane TE, et al. Enhancing Cancer Supportive Care: Integrating Psychosocial Support, Nutrition, and Physical Activity Using Telehealth Solutions. JCO Global Oncology. 2024 Oct 1;(10).
  56. Charalampopoulou M, Tamiolaki EE, Dimitrios Tryfonopoulos, Garyfalia Bletsa, Dimitrios Tsakogiannis, Lamprini Tzioga, et al. The Impact of Lifestyle Medicine on Quality of Life in Female Breast Cancer Survivors: A Systematic Review. American Journal of Lifestyle Medicine [Internet]. 2025 Apr 21 [cited 2025 Sep 26]; Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12012499/
  57. Millstein RA, Winters L, Comander A. Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL [Internet]. Cancernetwork.com. CancerNetwork; 2025 [cited 2025 Sep 26]. Available from: https://www.cancernetwork.com/view/using-multidisciplinary-lifestyle-medicine-to-enhance-cancer-survivor-qol
  58. Ergas IJ, Zwerling Baltrushes R, Dzubnar JM, Farhady P, Shim V. Lifestyle medicine program for patients with breast cancer at Kaiser Permanente Oakland. JCO Oncology Practice. 2024 Oct;20(10_suppl):359–9.
  59. Smith-Turchyn J, Stouth DW, Keogh JAJ, Ball E, Rodrigues M, Richardson J, et al. Implementing exercise and self-management for women with breast cancer during treatment: results of the NEXT-BRCA randomized controlled trial. Scientific Reports [Internet]. 2025 Jul 18 [cited 2025 Sep 26];15(1). Available from: https://www.nature.com/articles/s41598-025-11660-0
  60. White I, Cunningham J, Georgopoulou S, Tilt L, Rawson R, Thilaganathan E, et al. Evaluation of a 12-week Mediterranean diet-based nutritional and educational programme for breast cancer survivors: impact on BMI, fatigue, dietary adherence, and menopausal symptoms. Frontiers in Nutrition [Internet]. 2025 Aug 18 [cited 2025 Sep 8];12. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12400866/
  61. Heins MJ, de Ligt KM, Verloop J, Siesling S, Korevaar JC, Berendsen A, et al. Adverse health effects after breast cancer up to 14 years after diagnosis. The Breast [Internet]. 2024 Dec 29;103865. Available from: https://www.sciencedirect.com/science/article/pii/S0960977624001966
  62. Pimentel-Parra GA, García-Vivar C, Escalada-Hernández P, Martín-Rodríguez LS, Soto-Ruiz N. Systematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations. British Journal of Cancer [Internet]. 2025 May 17 [cited 2025 Jun 1]; Available from: https://www.nature.com/articles/s41416-025-03059-5
  63. Suharyono S, Wibowo SA, Purnamasari I, Sukartini T. A Systematic Review of Supportive Therapy Effect on Quality of Life in Cancer Patients. Jurnal Ners. 2020 Jul 7;15(1Sp):197–207.
  64. Ferrell BR, Grant MM, Funk BM, Otis-Green SA, Garcia NJ. Quality of life in breast cancer survivors: implications for developing support services. Oncology Nursing Forum [Internet]. 1998 Jun 1;25(5):887–95. Available from: https://pubmed.ncbi.nlm.nih.gov/9644705/
  65. Poorkiani M, Abbaszadeh A, Hazrati M, Jafari P, Sadeghi M, Mohammadianpanah M. The effect of rehabilitation on quality of life in female breast cancer survivors in Iran. Indian Journal of Medical and Paediatric Oncology. 2010;31(4):105.
  66. Dong S, Wang Z, Shen K, Chen X. Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis. Frontiers in Oncology. 2021 Mar 25;11.
  67. Pan K, Aragaki AK, Neuhouser ML, Simon MS, Luo J, Caan B, et al. Low-fat dietary pattern and breast cancer mortality by metabolic syndrome degree: Secondary analyses of the Women’s Health Initiative (WHI) Dietary Modification randomized trial. Journal of Clinical Oncology. 2019 May 20;37(15_suppl):1539–9.
  68. Chen YX, Zhou Y, Zhang XL, He W, Ye Q, Xu M. Digital health interventions for cancer-related cognitive impairment in breast cancer patients: A scoping review. DIGITAL HEALTH [Internet]. 2025 May [cited 2025 Sep 26];11. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12268144/
  69. Shaffer KM, Turner KL, Siwik C, Gonzalez BD, Upasani R, Glazer JV, et al. Digital health and telehealth in cancer care: a scoping review of reviews. The Lancet Digital Health. 2023 May;5(5):e316–27.
  70. Jiménez-Díaz A, Escrivá-Martínez T, Herrero R, Baños R. Evidence-based digital health interventions for breast cancer survivors’ care: an umbrella review. Internet Interventions. 2025 Jun;100846.
  71. Team CN, Team CN. Top Oncology Innovations That Shaped the First Half of 2025 | Cancer News [Internet]. Cancer News. 2025. Available from: https://binaytara.org/cancernews/article/top-oncology-innovations-that-shaped-the-first-half-of-2025
  72. Rob G. Breast Cancer Vaccine 2025: What to Expect [Internet]. Medical Realities. 2025 [cited 2025 Sep 26]. Available from: https://medicalrealities.com/the-breast-cancer-vaccine-in-2025-a-new-era-of-prevention-and-hope/
  73. Seamus O’Reilly, Luis IV, Adam V, Razis ED, Ander Urruticoechea, Arahmani A, et al. Advancing equitable access to innovation in breast cancer. npj Breast Cancer [Internet]. 2025 Jul 10 [cited 2025 Sep 26];11(1). Available from: https://www.nature.com/articles/s41523-025-00768-1
  74. Addissouky TA, Ibrahim, Ali, Mahmood, Wang Y. Harnessing innovation for the future of breast cancer management. 2024 Apr 3;1(1):10–7.
  75. Matthius A. Experts Forecast Cancer Research and Treatment Advances in 2025 [Internet]. American Association for Cancer Research (AACR). 2025. Available from: https://www.aacr.org/blog/2025/01/10/experts-forecast-cancer-research-and-treatment-advances-in-2025/
  76. Innovations and insights in breast cancer research: 2025 update [Internet]. Abcam.com. 2025 [cited 2025 Sep 26]. Available from: https://www.abcam.com/en-us/stories/articles/innovations-and-insights-in-breast-cancer-research-2025-update
  77. Masterson V, Shine I, North M. Here are 12 new advances in the battle to beat cancer [Internet]. World Economic Forum. 2025. Available from: https://www.weforum.org/stories/2025/02/cancer-treatment-and-diagnosis-breakthroughs/
  78. Witkop CT, Nelson HD. From Breast Cancer Screening to Diagnosis. JAMA Internal Medicine [Internet]. 2025 Sep 1 [cited 2025 Sep 26];185(9):1059. Available from: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2836526
  79. Ma Z. Participation in early mammography screening. BMJ [Internet]. 2025 Sep 24 [cited 2025 Sep 26];390:r1893. Available from: https://www.bmj.com/content/390/bmj.r1893
  80. Ferrari A, Herrera DJ, De V, D’haenens W, Alejos AR, Nigus Bililign Yimer, et al. Advancing Mammographic Screening Among Underserved Groups: A Systematic Review and Meta-Analysis of Intervention Strategies to Increase Breast Cancer Screening Uptake. Public health reviews. 2025 Apr 4;46.
  81. BCAM 2025 [Internet]. Nccs.com.sg. 2025 [cited 2025 Sep 26]. Available from: https://www.nccs.com.sg/community-care/outreach/bcam-2025
  82. Our strategy [Internet]. Breast Cancer Now. 2019. Available from: https://breastcancernow.org/about-us/who-we-are/our-strategy
  83. World Health Organisation. The Global Breast Cancer Initiative [Internet]. www.who.int. 2023. Available from: https://www.who.int/initiatives/global-breast-cancer-initiative

The Silent Global Crisis: How Metabolic Health Is Reshaping the Future of Female Breast Cancer